Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials
Authors' conclusion
Targeted glucose release activates endogenous enteroendocrine signalling networks, improves a clinically relevant metabolic endpoint, and has minimal adverse effects. The approach to target native enteroendocrine signalling has disruptive potential for the treatment of metabolic disorders, including obesity.
Study context
- Population
- Prediabetic subjects (Phase 2a); Phase 1 studies of acute PK/PD responses
- Comparison
- Oral glucose-delivering microbead lead formulation vs placebo (Phase 2a); coating variations and glucose dosing (Phase 1)
Methodological detailstwo-period, two-sequence crossover (Phase 2a), placebo-controlled (Phase 2a)
- Two-period, two-sequence crossover (Phase 2a)
- Placebo-controlled (Phase 2a)
Primary result
As reported in the abstract
Glucose tolerance (Phase 2a) · 6 weeks
- Lead formulation improved glucose tolerance in pre-diabetic patients, comparable to results using GLP-1 mimetics
- Microbeads targeted the distal small intestine and elicited a robust plurihormonal enteroendocrine response (Phase 1)
Safety
- Adverse events were infrequent and modest
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials. Diabetes Obes Metab. Published 17 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →